Novartis Shares Drop After Del-Desiran Miss Adds to Trial Setbacks

By Stocks News   |   2 months ago   |   Stock Market News
Novartis Shares Drop After Del-Desiran Miss Adds to Trial Setbacks

Novartis (NYSE: NVS) shares fell nearly 14% on Tuesday after the company reported that del-desiran did not meet the main goal of a Phase III study in patients with myotonic dystrophy type 1. The decline put the stock on pace for its biggest one-day loss since March 2020 and followed a series of clinical setbacks disclosed over the past week.

In the global HARBOR trial, del-desiran did not produce a statistically significant improvement versus placebo in the speed at which patients could open their hands. Novartis said it is reviewing the full study results and plans to consult health authorities before deciding how to proceed with the program.

The drug became part of Novartis’ neuromuscular portfolio through its approximately $12 billion purchase of Avidity Biosciences last year. Del-desiran was one of three antibody oligonucleotide conjugate therapies included in the acquisition.

The latest result came after Novartis disclosed that pelacarsen failed in a late-stage study to lower the risk of cardiovascular events. The company also paused eight clinical studies involving the experimental cell therapy rap-cel after three patient deaths. Novartis kept its longer-term sales outlook unchanged, saying it continues to target average annual growth of 5% to 6% through 2030.

Jefferies analysts said investors may question whether that target can be reached without additional acquisitions.

The company has also reported favorable clinical findings elsewhere in its pipeline. Last week, Novartis said a late-stage study of experimental multiple sclerosis drug remibrutinib showed that patients with relapsing multiple sclerosis experienced slower disability progression.

Shreeram Aradhye, Novartis’ president of development and chief medical officer, said the company is continuing to assess the HARBOR data as it considers the next steps for del-desiran.

About Novartis

Novartis (NYSE: NVS) was formed in 1996 and is headquartered in Basel, Switzerland. The pharmaceutical company develops and commercializes prescription medicines across areas including cardiovascular disease, immunology, neuroscience and oncology.

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article. 

 

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer